JOP20190207A1 - تركيبة صيدلانية تشتمل على بونيسيمود - Google Patents
تركيبة صيدلانية تشتمل على بونيسيمودInfo
- Publication number
- JOP20190207A1 JOP20190207A1 JOP/2019/0207A JOP20190207A JOP20190207A1 JO P20190207 A1 JOP20190207 A1 JO P20190207A1 JO P20190207 A JOP20190207 A JO P20190207A JO P20190207 A1 JOP20190207 A1 JO P20190207A1
- Authority
- JO
- Jordan
- Prior art keywords
- ponesimod
- pharmaceutical combination
- active ingredient
- teriflunomide
- leflunomide
- Prior art date
Links
- LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 title abstract 2
- 229950009275 ponesimod Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 229960000681 leflunomide Drugs 0.000 abstract 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000331 teriflunomide Drugs 0.000 abstract 1
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017055994 | 2017-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190207A1 true JOP20190207A1 (ar) | 2019-09-10 |
Family
ID=61655772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0207A JOP20190207A1 (ar) | 2017-03-14 | 2017-06-16 | تركيبة صيدلانية تشتمل على بونيسيمود |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11723896B2 (OSRAM) |
| EP (1) | EP3595657A1 (OSRAM) |
| JP (3) | JP7281406B2 (OSRAM) |
| KR (1) | KR102574562B1 (OSRAM) |
| CN (1) | CN110381942B (OSRAM) |
| AU (2) | AU2018233109B2 (OSRAM) |
| BR (1) | BR112019018894A2 (OSRAM) |
| CA (1) | CA3056301C (OSRAM) |
| CL (1) | CL2019002525A1 (OSRAM) |
| CO (1) | CO2019008510A2 (OSRAM) |
| CR (1) | CR20190464A (OSRAM) |
| DO (1) | DOP2019000257A (OSRAM) |
| EA (1) | EA201992117A1 (OSRAM) |
| EC (1) | ECSP19073317A (OSRAM) |
| IL (1) | IL269239B2 (OSRAM) |
| JO (1) | JOP20190207A1 (OSRAM) |
| MA (1) | MA49822A (OSRAM) |
| MX (1) | MX390941B (OSRAM) |
| NI (1) | NI201900092A (OSRAM) |
| PE (1) | PE20191489A1 (OSRAM) |
| PH (1) | PH12019502110A1 (OSRAM) |
| SG (1) | SG11201907308UA (OSRAM) |
| UA (1) | UA125756C2 (OSRAM) |
| WO (1) | WO2018167030A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES448386A1 (es) | 1975-06-05 | 1978-04-16 | Hoechst Ag | Procedimiento para la preparacion de anilidas de acido 5-me-til-isoxazol-4-carboxilico. |
| DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| DE60110043T2 (de) * | 2000-02-15 | 2006-03-02 | Teva Pharmaceutical Industries Ltd. | Methode zur synthetisierung von leflunomid |
| GB0123571D0 (en) * | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| SI1381356T1 (sl) * | 2001-04-05 | 2008-12-31 | Aventis Pharma Inc | Uporaba (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluorometilfenil)-amida za zdravljenje multiple skleroze |
| US6894184B2 (en) | 2003-03-18 | 2005-05-17 | Aventis Pharma Deutschland Gmbh | Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides |
| CA2545582C (en) | 2003-11-21 | 2013-04-16 | Actelion Pharmaceuticals Ltd | 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| MX2007004265A (es) | 2004-10-19 | 2008-03-04 | Aventis Pharma Inc | Uso de (4'trifluorometilfenil) -amida del acido (z) - 2 - ciano - 3 - hidroxi-but - 2- enoico para tratar la enfermedad inflamatoria del intestino. |
| DE102006017896A1 (de) | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Leflunomid enthaltende pharmazeutische Zusammensetzungen |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| CN101541772B (zh) | 2006-11-23 | 2013-04-17 | 埃科特莱茵药品有限公司 | 一种制备2-亚氨基-四氢噻唑-4-酮衍生物的新方法 |
| PT2278960T (pt) | 2008-03-17 | 2017-03-09 | Actelion Pharmaceuticals Ltd | Regime de dosagem para um agonista seletivo do recetor s1p1 |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| UA107582C2 (uk) | 2009-09-18 | 2015-01-26 | Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю | |
| WO2012015758A2 (en) | 2010-07-30 | 2012-02-02 | Saint Louis University | Methods of treating pain |
| AR082436A1 (es) | 2010-08-02 | 2012-12-05 | Sanofi Aventis Us Llc | Uso de teriflunomida para tratar la esclerosis multiple |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| RS60408B1 (sr) | 2012-08-17 | 2020-07-31 | Actelion Pharmaceuticals Ltd | Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupku |
| WO2016079687A1 (en) | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| SI3256125T1 (sl) | 2014-12-11 | 2022-04-29 | Actelion Pharmaceuticals Ltd | Režim odmerjanja ponesimoda, selektivnega agonista receptorja S1P1 |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| CN107920991A (zh) | 2015-06-18 | 2018-04-17 | 马丁尼斯生物制药纳米技术公司 | 治疗炎性疾病或病状的组合物和方法 |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
-
2017
- 2017-06-16 JO JOP/2019/0207A patent/JOP20190207A1/ar unknown
-
2018
- 2018-03-13 CR CR20190464A patent/CR20190464A/es unknown
- 2018-03-13 EA EA201992117A patent/EA201992117A1/ru unknown
- 2018-03-13 AU AU2018233109A patent/AU2018233109B2/en active Active
- 2018-03-13 MX MX2019010874A patent/MX390941B/es unknown
- 2018-03-13 CA CA3056301A patent/CA3056301C/en active Active
- 2018-03-13 KR KR1020197026599A patent/KR102574562B1/ko active Active
- 2018-03-13 UA UAA201910123A patent/UA125756C2/uk unknown
- 2018-03-13 MA MA049822A patent/MA49822A/fr unknown
- 2018-03-13 SG SG11201907308UA patent/SG11201907308UA/en unknown
- 2018-03-13 WO PCT/EP2018/056185 patent/WO2018167030A1/en not_active Ceased
- 2018-03-13 PE PE2019001845A patent/PE20191489A1/es unknown
- 2018-03-13 US US16/494,163 patent/US11723896B2/en active Active
- 2018-03-13 BR BR112019018894A patent/BR112019018894A2/pt not_active Application Discontinuation
- 2018-03-13 EP EP18711299.0A patent/EP3595657A1/en active Pending
- 2018-03-13 CN CN201880017102.0A patent/CN110381942B/zh active Active
- 2018-03-13 JP JP2019549459A patent/JP7281406B2/ja active Active
-
2019
- 2019-08-05 CO CONC2019/0008510A patent/CO2019008510A2/es unknown
- 2019-09-03 CL CL2019002525A patent/CL2019002525A1/es unknown
- 2019-09-10 IL IL269239A patent/IL269239B2/en unknown
- 2019-09-11 NI NI201900092A patent/NI201900092A/es unknown
- 2019-09-13 PH PH12019502110A patent/PH12019502110A1/en unknown
- 2019-10-08 DO DO2019000257A patent/DOP2019000257A/es unknown
- 2019-10-10 EC ECSENADI201973317A patent/ECSP19073317A/es unknown
-
2022
- 2022-12-21 JP JP2022204487A patent/JP2023030091A/ja active Pending
-
2023
- 2023-06-27 US US18/341,853 patent/US20240139161A1/en active Pending
- 2023-11-29 AU AU2023274118A patent/AU2023274118B2/en active Active
-
2024
- 2024-04-18 JP JP2024067486A patent/JP2024096962A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502110A1 (en) | Pharmaceutical combination comprising ponesimod | |
| MX2023011657A (es) | Composiciones que comprenden curones y usos de los mismos. | |
| GEP20207159B (en) | Diacylglycerol acyltransferase 2 inhibitors | |
| PL3668937T3 (pl) | Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu | |
| EP3677584A4 (en) | ASSOCIATION WITH BRUTON TYROSINKINASE (BTK) INHIBITION AND DEGRADATION | |
| NZ744307A (en) | Treatment of fibrosis | |
| MY197631A (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
| SA520411187B1 (ar) | نظائر فينيل ألانينول كربامويل واستخداماتها | |
| MX2020005483A (es) | Antagonistas de ildr2 y combinaciones de los mismos. | |
| PH12019501314A1 (en) | Pharmaceutical combination comprising a t-type calcium channel blocker | |
| SG11201907472QA (en) | Composition for inhibiting myofibrosis | |
| MY181719A (en) | Fragrance and flavor compositions comprising neopentyl glycol diacetate | |
| WO2020122838A3 (en) | A combination comprising a multiple sclerosis agent and at least one anti-epileptic agent | |
| MX376853B (es) | Odorante osmanthus. | |
| PH12018502008A1 (en) | Oral care product | |
| WO2018237010A3 (en) | VACCINE COMPOSITIONS AGAINST STREPTOCOCCUS AND THEIR METHODS OF USE | |
| SG10201804532PA (en) | W/O type emulsion and a premix for producing the same | |
| MY179170A (en) | Insect repellent | |
| FI20155779A7 (fi) | Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu | |
| MX2020003513A (es) | Composiciones de ingredientes activos que comprenden n-alquenoil-n-alquilglucamidas y el uso de los mismos. | |
| MX2020008300A (es) | Uso de [6]-paradol para estabilizacion de composiciones cosmeticas. | |
| MY202239A (en) | Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof | |
| EA201692056A1 (ru) | Композиция для личной гигиены | |
| WO2020122839A3 (en) | A combination comprising a multiple sclerosis agent and at least one muscle relaxant agent | |
| TR201620309A2 (tr) | Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇ |